Antiangiogenesis in Early-Stage Colon Cancer-Microscopically Busted
| Errataetall: |
CommentOn: JAMA Netw Open. 2020 Oct 1;3(10):e2020425. - PMID 33074326 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
JAMA network open - 3(2020), 10 vom: 01. Okt., Seite e2021064 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hochster, Howard S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04ZR38536J |
|---|
| Anmerkungen: |
Date Completed 21.12.2020 Date Revised 21.12.2020 published: Electronic CommentOn: JAMA Netw Open. 2020 Oct 1;3(10):e2020425. - PMID 33074326 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamanetworkopen.2020.21064 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316437247 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316437247 | ||
| 003 | DE-627 | ||
| 005 | 20231225161059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamanetworkopen.2020.21064 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316437247 | ||
| 035 | |a (NLM)33074321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hochster, Howard S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiangiogenesis in Early-Stage Colon Cancer-Microscopically Busted |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2020 | ||
| 500 | |a Date Revised 21.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentOn: JAMA Netw Open. 2020 Oct 1;3(10):e2020425. - PMID 33074326 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA network open |d 2018 |g 3(2020), 10 vom: 01. Okt., Seite e2021064 |w (DE-627)NLM289300517 |x 2574-3805 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:e2021064 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamanetworkopen.2020.21064 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2020 |e 10 |b 01 |c 10 |h e2021064 | ||